ETF’s 4.03% ImmunityBio Holding Rises on Regulatory Plan and 700% Revenue Growth
Virtus LifeSci Biotech Products ETF holds ImmunityBio at a 4.03% weight, with shares up 1.51% following plans to submit a regulatory package for recombinant BCG in Saudi Arabia. ImmunityBio’s 113 million revenue for fiscal 2025 (+700% yoy) and Phase 2b NSCLC data (14.1-month median OS) bolster BBP’s biotech exposure.
1. BBP’s ImmunityBio Weighting
The Virtus LifeSci Biotech Products ETF holds a 4.03% position in ImmunityBio, making it one of BBP’s largest individual stock exposures and a key driver of its biotech allocation.
2. Regulatory Package Submission
ImmunityBio plans to submit a regulatory package for recombinant BCG to the Saudi Food and Drug Authority in the coming weeks to address a global BCG shortage and expand bladder cancer treatment access in Saudi Arabia.
3. Anktiva Revenue and Clinical Data
The company reported approximately $113 million in Anktiva revenue for fiscal 2025, a 700% increase year-over-year, and Phase 2b NSCLC data demonstrated a median overall survival of 14.1 months, with 57% and 34% survival rates at 12 and 18 months.
4. Price Momentum and Analyst Outlook
ImmunityBio shares have climbed 77.46% over the past 12 months and rose 1.51% recently, supported by neutral RSI and bullish MACD signals; analysts maintain buy ratings with an average price target of $11.80, enhancing BBP’s performance potential.